Nyuen Biotechnology and Thermo Scientific reached a strategic cooperation to jointly promote the precision diagnosis and treatment of central nervous system diseases

On June 26, 2019, Shanghai Nyuen Biotechnology Co., Ltd. (hereinafter referred to as Nyuen Bio), which focuses on precision medicine in the field of central nervous system in China, and Thermo Fisher Scientific (hereinafter referred to as Thermo Fisher), a world leader in the field of scientific services, Fly) signed a strategic cooperation agreement. Based on the cooperation agreement, the two parties will rely on Thermo Fisher's new molecular diagnostic technology platform to jointly build a "Central Nervous Precision Medicine Demonstration Laboratory" to promote the precise classification and integration of diagnosis and treatment of central nervous system diseases.

With the development of precision medicine, the diagnosis and treatment of central nervous system diseases is also undergoing integration and transformation. As a provider of comprehensive solutions for precision medicine, Thermo Fisher has a series of full-process solutions from biobanks, basic research, clinical application development to clinical diagnosis, and is committed to creating a "precision medical ecosystem".

This cooperation will rely on Thermo Fisher's leading new molecular diagnostic technology platform and join hands with Nyuen Bio to establish a precision medicine demonstration laboratory focusing on central nervous system diseases.

Based on the principle of "mutual benefit and common development", the demonstration laboratory will conduct in-depth research and cooperation on the different application scenarios of genetic testing technology in clinical molecular testing, and the stability and accuracy of testing technology, covering the auxiliary diagnosis of diseases , Drug companion diagnosis, IVD kit R&D and production, as well as biopharmaceutical and gene therapy R&D and achievement transformation.

The cooperation will promote the establishment of precise classification, precise medication and disease standard systems related to the field of central nervous system diseases, and play a guiding role in the discovery of biomarkers and the development of related biological drugs. In the future, the laboratory may also apply for a medical laboratory through self-built testing methods, and directly carry out related research with the hospital, thereby further promoting the clinical research and transformation of precision medicine in the field of central nervous system diseases.

Nyuen Bio is a wholly-owned subsidiary of Enhua Pharmaceutical, focusing on precision medicine for diseases in the central nervous system.

Mr. Sun Jiaquan, President of Jiangsu Enhua Pharmaceutical Group, said, “I hope that through this strategic cooperation, the development and application of biotechnology will empower psychiatrists and bring more benefits to patients. Our ultimate goal is to let everyone All can be physically and mentally healthy and lead a better life."

Tony Acciarito, President of Thermo Fisher China, said: "The rise of precision medicine brings new hope to patients suffering from central nervous system diseases. This time, in cooperation with Nyuen Biotechnology, Thermo Fisher will provide new types of The molecular diagnostic technology platform helps to achieve precise classification, precise diagnosis and treatment and medication of central nervous system diseases, and promotes the integration of precise diagnosis and treatment in this field, thereby accelerating the construction of a precision medical ecosystem to realize Thermo Fisher's “rooted in China, serving China” committed to."